Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gemcitabine/cisplatin with or without nivolumab (± BMS-986205) in muscle-invasive bladder cancer
jRCT2080224662Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised trial of nivolumab, linrodostat, gemcitabine and cisplatin in muscle-invasive bladder carcinoma (MIBC) (3 arms), sponsored by Ono Pharmaceutical. Started May 2019; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on jRCT2080224662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224662.